AQEMIA vs Recursion

AQEMIA logo

AQEMIA

Scale drug discovery with quantum-inspired physics and generative AI

83 employees · est. 2019 · Paris, France

VS
Recursion logo

Recursion

Decoding Biology to Radically Improve Lives

770 employees · est. 2013 · Salt Lake City, United State...

Recursion is the older company (2019 vs 2013); Recursion is the larger of the two.

Side-by-Side Comparison

AQEMIA Recursion
Founded
2019 2013 older
Headquarters
Paris, France Salt Lake City, United States
Employees
83 770 larger
Industry
AI, Biotechnology, Life Sciences AI, Biotechnology, Health and Wellness
Funding Stage
Not tracked yet IPO
Total Funding
$115.18M $1.30B
Funding Rounds
7 17
Services
AI-driven drug discovery, Development of next-generation medicines AI-based drug discovery and development, Clinical trial management and execution, Partnerships for drug research and development, Data-driven insights and analytics for drug discovery
Target Customers
Pharmaceutical companies, Biotech researchers, Healthcare providers Pharmaceutical companies, Biotech firms, Healthcare institutions, Life sciences researchers, Oncology specialists
Taxonomy
Drug DiscoveryQuantum-inspired PhysicsGenerative AIPharmaceutical R&DTechBioPharmaTech +8 TechBioDecoding BiologyRecursion OSDrug DiscoveryBiological And Chemical DatasetsPhenomics +5
Website
aqemia.com recursion.com
AQEMIA logo

About AQEMIA

AQEMIA, founded in 2019, is a cutting-edge company at the intersection of AI and biotechnology, focusing on drug discovery through the use of quantum-inspired physics and generative AI. The company specializes in creating novel medicines to address significant diseases, particularly in the oncology...

Recursion logo

About Recursion

Recursion (NASDAQ: RXRX) is at the forefront of the TechBio sector, leveraging its platform, Recursion OS, to harness advanced AI and machine learning in pursuit of transforming medicine. Founded in 2013 and headquartered in the United States, Recursion is ambitiously decoding biology with the aim o...

Also comparing in this category

Comparing more than these two?

Get AQEMIA, Recursion and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.

How does AQEMIA compare?

A PDF of AQEMIA and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Frequently Asked Questions

AQEMIA was founded in 2019, based in Paris, France, with 83 employees. AQEMIA, founded in 2019, is a cutting-edge company at the intersection of AI and biotechnology, focusing on drug discovery through the use of quantum-inspired physics and generative AI. The company sp. Recursion was founded in 2013, based in Salt Lake City, United States, with 770 employees. Recursion (NASDAQ: RXRX) is at the forefront of the TechBio sector, leveraging its platform, Recursion OS, to harness advanced AI and machine learning in pursuit of transforming medicine. Founded in 2.
AQEMIA has raised $115.18M and Recursion $1.30B. Latest stage: Recursion IPO.
Both work in AI, Biotechnology and Pharmaceutical and list drug discovery, techbio and immuno-oncology among their focus areas.

Compare AQEMIA with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at AQEMIA on 15 Jun 2026, and Recursion on 23 Sep 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes